Share on StockTwits

Equities researchers at Stifel Nicolaus began coverage on shares of Acorda Therapeutics (NASDAQ:ACOR) in a research report issued on Tuesday. The firm set a “buy” rating and a $47.00 price target on the stock. Stifel Nicolaus’ target price suggests a potential upside of 48.22% from the stock’s previous close.

Separately, analysts at Zacks reiterated a “neutral” rating on shares of Acorda Therapeutics in a research note on Monday, August 4th. They now have a $30.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Acorda Therapeutics presently has a consensus rating of “Hold” and an average target price of $37.75.

Shares of Acorda Therapeutics (NASDAQ:ACOR) opened at 31.71 on Tuesday. Acorda Therapeutics has a 52-week low of $27.51 and a 52-week high of $39.95. The stock’s 50-day moving average is $30.74 and its 200-day moving average is $33.62. The company has a market cap of $1.302 billion and a P/E ratio of 70.94.

Acorda Therapeutics (NASDAQ:ACOR) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.42 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.15 by $0.27. The company had revenue of $97.13 million for the quarter, compared to the consensus estimate of $91.40 million. During the same quarter last year, the company posted $0.34 earnings per share. Acorda Therapeutics’s revenue was up 11.5% compared to the same quarter last year. On average, analysts predict that Acorda Therapeutics will post $0.22 earnings per share for the current fiscal year.

Acorda Therapeutics, Inc (NASDAQ:ACOR) is a commercial-stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.